Additional Relevant Details GlobalImmune is currently enrolling patients in its Phase 2 study of GI-6301 for the treatment of chrodoma.  The study expects to enroll 55 patients.  The study, sponsored by the National Cancer Institute, measures the difference in overall response rate among patients with Chordoma who are treated with radiation plus placebo vs. radiation plus vaccine.